TAK

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.02
Percentage change 0.10	%

Peers: PFE MRK BMY GSK SNY LLY AZN JNJ NVS ABBV

| Held by: FVD PPH AVDE APIE GINX VEU JSTC CVY AVSD DFIC

Scroll to Statements

Index	-	P/E	71.21	EPS (ttm)	0.22	Insider Own	0.02%	Shs Outstand	3.15B	Perf Week	2.62%
Market Cap	48.70B	Forward P/E	23.51	EPS next Y	0.66	Insider Trans	0.00%	Shs Float	3.15B	Perf Month	2.96%
Enterprise Value	80.16B	PEG	1.50	EPS next Q	0.18	Inst Own	5.05%	Short Float	0.21%	Perf Quarter	4.07%
Income	707.29M	P/S	1.62	EPS this Y	131.31%	Inst Trans	2.84%	Short Ratio	2.89	Perf Half Y	17.77%
Sales	30.05B	P/B	1.05	EPS next Y	21.39%	ROA	0.73%	Short Interest	6.50M	Perf YTD	16.88%
Book/sh	14.74	P/C	18.91	EPS next 5Y	47.57%	ROE	1.50%	52W High	15.48 -0.03%	Perf Year	19.87%
Cash/sh	0.82	P/FCF	9.77	EPS past 3/5Y	-30.04% 11.40%	ROIC	0.93%	52W Low	12.80 20.90%	Perf 3Y	11.81%
Dividend Est.	0.69 (4.47%)	EV/EBITDA	9.00	Sales past 3/5Y	-1.83% -0.14%	Gross Margin	53.09%	Volatility	0.92% 0.97%	Perf 5Y	-15.53%
Dividend TTM	0.33 (2.11%)	EV/Sales	2.67	EPS Y/Y TTM	-30.80%	Oper. Margin	13.02%	ATR (14)	0.22	Perf 10Y	-36.73%
Dividend Ex-Date	Mar 31, 2025	Quick Ratio	0.52	Sales Y/Y TTM	1.86%	Profit Margin	2.35%	RSI (14)	63.57	Recom	2.00
Dividend Gr. 3/5Y	-1.64% -1.61%	Current Ratio	1.01	EPS Q/Q	-3198.46%	SMA20	2.66%	Beta	0.27	Target Price	17.30
Payout	261.52%	Debt/Eq	0.73	Sales Q/Q	-2.34%	SMA50	4.13%	Rel Volume	2.01	Prev Close	15.46
Employees	47455	LT Debt/Eq	0.65	Earnings	May 08 BMO	SMA200	8.87%	Avg Volume	2.25M	Price	15.48
IPO	Mar 06, 2008	Option/Short	Yes / Yes	EPS/Sales Surpr.	-718.71% -1.24%	Trades		Volume	1,208,890	Change	0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy	$20
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform	$21 → $24
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform	$19.50
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

Jun-30-25 08:00AM	Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 (Business Wire)
Jun-27-25 08:11AM	Will Strong Asceniv Sales Drive ADMA Biologics Further? (Zacks)
Jun-25-25 11:13AM	Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? (Zacks)
08:54AM	ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? (Zacks)
03:07AM	Takeda Announces New Assignments of Directors (Business Wire)
03:09PM	Loading…
Jun-24-25 03:09PM	Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera (Insider Monkey)
Jun-16-25 01:06PM	ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? (Zacks)
Jun-06-25 10:40AM	ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? (Zacks)
Jun-04-25 04:47AM	EC approves Takeda ADC plus chemo for stage IIb Hodgkins lymphoma (Pharmaceutical Technology)
Jun-03-25 10:12AM	European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD (Business Wire)
Jun-01-25 08:00AM	Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera (Business Wire)
May-27-25 07:30AM	Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award (Business Wire)
May-14-25 05:03PM	The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 (Business Wire)
May-12-25 04:28AM	Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices (Bloomberg)
04:18AM	Trump Vows US Drug Price Cuts of Up to 80% in Industry Blow (Bloomberg)
03:00PM	Loading…
May-09-25 03:00PM	Top 4 GARP Stocks With Attractive PEG Ratios to Watch (Zacks)
May-08-25 01:26PM	ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? (Zacks) -5.25%
02:36AM	Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress (Business Wire)
May-07-25 12:06PM	Takeda Pharmaceutical FY Earnings Preview (Seeking Alpha)
12:00PM	Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
09:40AM	Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? (Zacks)
09:15AM	What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 Earnings (GuruFocus.com)
May-05-25 08:00AM	BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers (Business Wire)
May-02-25 11:40AM	TAK or DSNKY: Which Is the Better Value Stock Right Now? (Zacks)
May-01-25 01:22PM	Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? (Zacks)
Apr-30-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice (Zacks)
09:32AM	Best Value Stocks to Buy for April 30th (Zacks)
08:05AM	Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education (Business Wire)
08:05AM	Best Income Stocks to Buy for April 30th (Zacks)
04:46AM	New Strong Buy Stocks for April 30th (Zacks)
07:46AM	Loading…
Apr-24-25 07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
Apr-23-25 11:10AM	Grifols: A Market Setback Turns Into Buying Opportunity (Seeking Alpha)
10:50AM	White Falcon Capital Q1 2025 Partner's Letter (Seeking Alpha)
Apr-21-25 09:40AM	Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? (Zacks)
Apr-16-25 11:40AM	TAK vs. DSNKY: Which Stock Is the Better Value Option? (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
07:25AM	NMPA approves BBM and Takeda Chinas haemophilia B therapy (Pharmaceutical Technology)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
11:53AM	Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs (The Wall Street Journal)
Apr-08-25 07:15AM	BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 (ACCESSWIRE)
Apr-04-25 09:40AM	Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? (Zacks)
Apr-03-25 11:25AM	Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (Seeking Alpha)
Apr-01-25 02:27PM	Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns (Seeking Alpha)
Mar-31-25 11:40AM	TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? (Zacks)
Mar-28-25 09:41AM	Takeda Canada says Health Canada expands marketing authorization for HyQvia (TipRanks)
Mar-27-25 09:30AM	Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) (PR Newswire)
Mar-24-25 03:00PM	ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? (Zacks)
Mar-19-25 09:40AM	Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now? (Zacks)
Mar-13-25 04:00AM	Takedas $770M deal deepens Big Pharmas omics push (Pharma Voice)
Mar-03-25 12:01PM	Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer (Benzinga)
10:25AM	Takeda and Protagonist report topline outcomes from trial of rusfertide (Clinical Trials Arena)
09:40AM	Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? (Zacks)
06:45AM	Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera (Business Wire)
06:29AM	Protagonist says Takeda-partnered drug succeeds in rare blood cancer (BioPharma Dive)
Feb-27-25 08:43AM	Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
Feb-25-25 07:11PM	Takeda broadens its deal with BridGene for up to $770m (Pharmaceutical Technology)
10:09AM	EMA approves Takedas Takhzyro pre-filled pen option for HAE (Pharmaceutical Technology)
Feb-24-25 03:01AM	The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) (PR Newswire)
Feb-15-25 02:43PM	Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025? (Insider Monkey)
Feb-14-25 09:40AM	Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? (Zacks)
Feb-12-25 10:04AM	BBI announces $31m facility for Shire to enhance asset finance (Leasing Life)
Feb-10-25 03:00AM	Are orexins the next golden child of neuroscience? (Pharma Voice)
Jan-30-25 10:14AM	Takeda announces appointment of Julie Kim as CEO (Pharmaceutical Technology)
06:22AM	Christophe Weber, veteran Takeda CEO, to retire next year (BioPharma Dive)
02:04AM	Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 (Business Wire)
01:35AM	Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth (Business Wire)
Jan-29-25 08:00AM	Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age (PR Newswire)
Jan-28-25 10:24AM	Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights (Benzinga)
Jan-21-25 08:00AM	Takeda Recognized as a Top Employer in Canada for Third Consecutive Year (PR Newswire)
08:00AM	Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire)
06:43AM	Health Canada gives Takedas mCRC capsules market authorisation (Pharmaceutical Technology)
Jan-20-25 08:00AM	Takeda's FRUZAQLA (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC) (PR Newswire)
Jan-02-25 04:03PM	Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025. (Barrons.com)
Dec-27-24 07:59AM	Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency (Benzinga)
01:00AM	Takeda Announces Approval of HYQVIA 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia (Business Wire)
Dec-19-24 08:02AM	Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative (PR Newswire)
06:32AM	Takeda Announces Subsidiary Liquidation and Merger Completion (TipRanks)
Dec-12-24 07:00PM	HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) (GlobeNewswire)
05:30PM	Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas (Business Wire)
Dec-04-24 06:07AM	Novavax sells Czech plant to Novo; Relay licenses out a cancer drug (BioPharma Dive)
04:31AM	Takeda licensed for anaemia therapy by Keros Therapeutics (Pharmaceutical Technology)
Dec-03-24 12:37PM	Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst (Benzinga)
07:00AM	Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics (Business Wire)
07:00AM	Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire)
06:30AM	Takedas Strong FY2024 H1 Boosts Full-Year Outlook (TipRanks)
Nov-30-24 04:29PM	Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now? (Insider Monkey)
Nov-29-24 08:08AM	Takeda Canada co-sponsors grant to boost IBD clinical research (Clinical Trials Arena)
Nov-21-24 11:30PM	HUTCHMED Announces Launch by Takeda of FRUZAQLA (fruquintinib) in Japan (GlobeNewswire)
08:22AM	Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies (Pharmaceutical Technology)
Nov-13-24 11:46AM	Why this major drugmaker no longer has an IT department (Fortune)
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-04-24 08:01AM	New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD (PR Newswire)
Oct-31-24 04:30AM	HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda (GlobeNewswire)
02:05AM	Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook (Business Wire)
Oct-30-24 09:00AM	What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings (GuruFocus.com)
Oct-25-24 07:04AM	Takeda and BMC partner to decarbonise US healthcare sector (Pharmaceutical Technology)
Oct-24-24 08:00AM	Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem (Business Wire)
Oct-23-24 03:05AM	Dengue is spreading and Sanofi is pulling the U.S. markets only vaccine. Whats next? (Pharma Voice)
Oct-22-24 08:54AM	Deko and Shire Leasing partner to offer B2B leasing at checkout (Leasing Life)
Oct-17-24 02:32PM	Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside (Benzinga)

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Giles Richard Platford	President, Plasma-Derived Ther	Aug 23 '24	Proposed Sale	14.94	19,073	284,951		Aug 22 08:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Takeda Pharmaceutical Co ADR

Upgrade your FINVIZ experience